Syneron Medical to host investor meeting to highlight opportunities in body contouring/fat treatment market

NewsGuard 100/100 Score

Syneron Medical Ltd. (NASDAQ: ELOS), a leading global aesthetic device company, announced today that it will host an investor meeting on Wednesday, September 17, 2014, at approximately 10:00 am to 1:00 pm ET in New York City. The meeting will highlight Syneron's opportunity in the fast growing body contouring and fat treatment market, with a focus on the UltraShape system, which received FDA clearance for fat cell destruction in April 2014.

The meeting will be hosted by Syneron's management team, including:

  • Shimon Eckhouse, Active Chairman of the Board
  • Amit Meridor, Chief Executive Officer
  • Hugo Goldman, Chief Financial Officer

The meeting will include presentations from physician guest speakers with direct experience with the UltraShape system and Syneron's products. The Company will issue an additional press release with further details regarding the event.

The investor meeting will be webcast live over the Internet and can be accessed through the Investor Relations section on Syneron's website at www.syneron.com. Presentation slides accompanying the presentation will also be available through the Investor Relations section of Syneron's website. Please go to the website a few minutes early in order to download the presentation and as it may be necessary to download audio software to hear the presentation. The investor meeting webcast will be archived on the Investor Relations section on Syneron's website for six months following the event.

Source:

Syneron Medical Ltd.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New method to evaluate enzymes opens path to ferroptosis-targeting cancer drugs